GAITHERSBURG, Md., Jan. 17,
2025 /PRNewswire/ -- Caring Cross and Vector BioMed,
Inc. are pleased to announce that Boro
Dropulic, Executive Director of Caring Cross and CEO of
Vector BioMed, will be speaking at Advanced Therapies Week (ATW) on
January 21 and 22 in Dallas, Texas. Dr. Dropulic will participate
in three key sessions where he will share his expertise and
insights into the future of cell and gene therapies, strategies for
improving access, and the commercialization of innovative
therapeutics.
Session Details
- Plenary Panel: "Innovating for the Future of Cell
and Gene Therapies"
Date: January 21, 2025
Time: 9:00 - 10:30 CST
Highlights: Dr. Dropulic will join an esteemed panel to
explore challenges and solutions for advancing the next generation
of cell and gene therapies.
- Panel Discussion: "The CAR-T Story and the Future
of Cell Therapies"
Date: January 21, 2025
Session Timing: 13:15 - 14:15
CST
Overview: Delve into the CAR-T journey, including
technological advancements and innovations shaping the landscape of
cellular therapies.
- Workshop: "Transforming Good Science into
Sustainable Business: Actionable Strategies for Commercializing
Cell and Gene Therapies"
Date: January 22, 2025
Time: 8:00 - 9:00 CST
Format: A hands-on session where Dr. Dropulic will outline
pathways for converting scientific innovation into scalable and
accessible commercial solutions.
Thought Leadership from Dr. Boro
Dropulic
Dr. Dropulic will address pressing issues such as the high cost
of CAR-T and other cellular therapies, the importance of
point-of-care manufacturing, and the global push to localize
development and production:
- Reducing Manufacturing Costs: Lowering the
cost of materials, particularly lentiviral vectors, is critical to
making therapies accessible. Vector BioMed is leading the way,
offering GMP-grade lentiviral vectors at approximately half the
price of leading alternatives through innovative and efficient
manufacturing processes.
- Point-of-Care Manufacturing: Centralized
manufacturing models are costly and inefficient. Distributing
manufacturing directly to care facilities can reduce costs and
ensure that transformative therapies reach more patients in
need.
- Global Access: Empowering low- and
middle-income countries (LMICs) to develop and manufacture advanced
therapeutics will address disparities in healthcare access and
drive meaningful change. Caring Cross's initiatives and
international networks aim to localize production capabilities and
enable affordable treatments for underserved regions.
Caring Cross: Building a Global Network for Advanced
Therapeutics
Through its International Affordable Advanced Therapeutics
Manufacturing Network, Caring Cross partners with organizations
worldwide to enhance point-of-care, low-cost manufacturing of
cellular therapeutics. This network promotes equity, inclusiveness,
and sustainability by:
- Strengthening manufacturing capacity and clinical trial
infrastructure.
- Expanding collaboration and visibility for member
organizations.
- Enabling transparent and responsive manufacturing
practices.
By addressing these needs, the network empowers organizations to
serve diverse populations and contribute to the equitable
development and distribution of lifesaving therapies.
Vector BioMed: Transforming Lentiviral Vector Development and
Rapid Production
Vector BioMed continues to expand its development resources and
optimize lentiviral vector manufacturing. The company is focused
on:
- Disrupting traditional workflows to offer cost-effective
solutions.
- Refining vector design during early development for enhanced
efficiency.
- Continuing innovation: Later in 2025, Vector BioMed plans to
launch several new products as part of a notable expansion of its
premier lentiviral vector platform technology.
With these advancements, Vector BioMed is committed to driving
innovation while maintaining an unwavering focus on cost reduction
for its clients.
Connect with Caring Cross and Vector BioMed at ATW
Learn more about Vector BioMed's lentiviral vector services
at Vector BioMed.
Discover how Caring Cross is advancing global access to therapies
at Caring Cross.
Request a meeting with team members at ATW using the ATW Event
App (link), our contact form, or via email at
partner@vectorbiomed.com.
View original
content:https://www.prnewswire.com/news-releases/boro-dropulic-to-share-pivotal-insights-at-advanced-therapies-week-on-january-21-22-2025-302354603.html
SOURCE Caring Cross
